Treating Cancer
from Within

READ MORE

01

Abalos was founded to translate an innovative arenavirus-based immune-activating approach into novel anti-cancer therapies

Scientific
Foundation

READ MORE

01

Stay up to date on news around Abalos

News &
Events

READ MORE

ABOUT ABALOS THERAPEUTICS

Triggering comprehensive immune responses from within the tumor

novel anti-cancer approach

Abalos Therapeutics is pioneering a novel anti-cancer approach that directs the full breadth of the immune system’s power specifically towards cancer cells. Abalos’ arenavirus-based drug candidates are designed to trigger precise innate and adaptive immune responses from within the tumor to engage all relevant immune cell types in a concerted attack against both the primary tumor and distant metastases. The company’s lead product candidate ABX-001 has demonstrated strong anti-tumor efficacy in pre-clinical studies in multiple tumor models as well as an excellent pre-clinical safety profile and will enter the clinic in 2025. Led by experienced biotech entrepreneurs and immunology pioneers, Abalos’ goal is to establish a new drug class in immuno-oncology.

READ TO LEARN

ABOUT ABALOS THERAPEUTICS

Abalos Dunes on Mars

why abalos?

The name “Abalos” was chosen with regards to our arenavirus-based technology to fight cancer. The name of this virus family derives from the Latin “arena” for “sand” due to the grainy appearance of particles inside the virus when viewed in cross-section under the transmission electron microscope. Reflecting our “sandy” approach, we came upon the fascinating blue dunes of the Abalos region on the otherwise “red” Mars, a planet that has always held a special fascination.

Named after the roman war god and its association with fire, it provides a connection to harnessing the weapon of the arenavirus to launch an attack against cancer. As Mars is also known as a planet of sand storms, this can be associated with the strong immune-response that is triggered by the arenavirus to attack the tumor.

ABALOS TECHNOLOGY

Therapeutic Approach

Abalos is leveraging its proprietary AdaptInnate technology platform to develop a new class of product candidates harnessing the immunostimulatory and anti-tumoral properties of arenaviruses to trigger a highly precise and directed immune response against primary tumors and their metastases. Abalos’ systemically administrable lead candidate, ABX-001, is specifically designed to persist and replicate in cancerous and antigen-presenting cells without destroying them. This novel, non-oncolytic approach results in the induction of targeted, effective, and durable anti-tumor activity involving both the innate and adaptive arms of the immune system.

READ MORE

This is Abalos

Meet the Team

A dynamic and ambitious group of experienced entrepreneurs and scientists advancing a novel immunostimulatory approach that (re)activates the full breadth of the immune system against solid tumors.